Audited Financial Results for the Quarter and Year ended March 31 , 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venmax Drugs reported strong revenue growth with FY26 revenue of Rs. 802.49 lakhs, up from Rs. 80.73 lakhs in FY25—an increase of approximately 894%. The company turned profitable with net profit of Rs. 24.82 lakhs versus a loss of Rs. 1.05 lakhs in the prior year. However, the results reveal a serious concern: operating cash flow is deeply negative at Rs. 1,099.61 lakhs (vs -Rs. 229.02 lakhs previously), driven by massive increases in receivables (Rs. 143 lakhs), other financial assets (Rs. 734.97 lakhs from Rs. 161 lakhs), and inventory (Rs. 99.88 lakhs from Rs. 5.75 lakhs). The auditors issued an unmodified opinion confirming clean financials. Share capital increased significantly to Rs. 1,158.29 lakhs due to conversion of 63.44 lakh share warrants.
Revenue growth is exceptional and profitability has been restored, but the massive negative operating cash flow despite strong revenue raises red flags about working capital management. Shareholders should monitor the company's cash conversion cycle closely.